An observational study in Colorectal Cancer, sponsored by Methodist Health System. Recruiting at 1 site in United States. Open to participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,338 studies in Colorectal Neoplasms with a site in United States — 419 open to participants now, 628 under way, 30 of them phase 3. Colorectal Neoplasms · United States.
Among the 2,338 studies in Colorectal Neoplasms with a site in United States, this one is the 211th largest by planned enrollment of the 324 observational ones that give a count, is one of 129 that started in 2020, is one of 325 observational ones, reaches primary completion later than 187 of the 626 other live ones, and was the 2,271st registered.
6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →419 of the 2,338 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Exelixis · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 40–80 · Men only
University of Pennsylvania · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 35 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 817 · Phase 2 790 · Phase 3 132 · Phase 4 19
First in 1981; this study’s year is marked. 129 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 250 across 1,442 observational studies indexed under Colorectal Neoplasms.
Median enrollment 64 across the 1,931 interventional studies, 221 across the 324 observational. Of the 1,563 that completed or were terminated, 549 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
885 of 2,338 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
227 of the studies in Colorectal Neoplasms with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05141721Phase 3Seattle Project CorporationA Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | 2027-03 |
| NCT04428905Phase 3City of Hope Medical CenterSelf-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | 2027-03-31 |
| NCT02997228Phase 3National Cancer Institute (NCI)Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | 2027-06-01 |
| NCT01349881Phase 3SWOG Cancer Research NetworkS0820, Adenoma and Second Primary Prevention Trial | 2027-09-15 |
| NCT03796884Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | 2026-11 |
Add all 227 to your calendar (.ics) → With an account.
Among the 2,338 studies in Colorectal Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a population-based retrospective study using the Surveillance, Epidemiology, and End Results (SEER) registry and National Cancer Data Base (NCDB) to look at colorectal cancer (CRC) patients younger than 35 and comparing them against CRC patients older than 35 years of age.
Specifically, investigator want to investigate the effect of having a diagnosis of CRC before the age of 35 years on:disease stage at presentation, insurance status at diagnosis, treatment patterns by stage, and adjusted cancer-specific survival. The hypothesis is that patients younger than 35 years of age with CRC will present with more advanced disease at diagnosis but will have longer survival overall through more aggressive therapy.
This is a population-based retrospective study using the Surveillance, Epidemiology, and End Results (SEER) registry and National Cancer Data Base (NCDB) to look at colorectal cancer (CRC) patients younger than 35 and comparing them against CRC patients older than 35 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The hypothesis is that patients younger than 35 years of age with CRC will present with more advanced disease at diagnosis but will have longer survival overall through more aggressive therapy.
Other: Colorectal cancer
CRC is a disease that is often associated with older adults (\<50 years). CRC remains the second most common cause of cancer death in males and the third most common cancer death in women. Despite this, CRC incidence has steadily declined in older adults; however, there is a concerning rise of incidence of colorectal cancer in young patients. The incidence of CRC in men and women under the age of 50 steadily increased 2.1 percent per year from 1992 through 2012.
Age
colorectal cancer (CRC) patients younger than 35 years and comparing them against CRC patients older than 35 years of age.
Time frame: 20 years
Plan to share: Yes — The data attained will be de-identified prior to sharing via presentation and/or publication in relevant research mediums.
Supporting information: Study protocol
Time frame: Not mentioned in protocol.
Access criteria: Not mentioned in protocol.
No publications or documents are linked to this record.
Started Jan 2020 (actual). Primary completion is estimated for Jan 2027, 84 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.